UTHR Stock Risk & Deep Value Analysis
United Therapeutics Corp
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About UTHR Stock
We analyzed United Therapeutics Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran UTHR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
UTHR Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the continued commercial underperformance of key therapies, as evidenced by the Q1 2026 revenue miss of $15.9 million against estimates, potentially indicating weaker-than-expected uptake of new products or increased competitive pressure in the pulmonary hypertension market. This could lead to further downward revisions in Q2/Q3 2026 revenue and EPS estimates, impacting near-term valuation.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Q1 2026 revenue and EPS miss ($781.5M revenue vs $797.4M est.; $5.82 EPS vs $7.00 est.) indicating commercial challenges.
- ⚠
HC Wainwright cut Q2 2026 EPS estimate to $6.07 from $6.76 on May 18, 2026, signaling a more cautious near-term outlook.
- ⚠
Insider selling by CFO James Edgemond ($5.73M on May 26, 2026) and General Counsel Paul A. Mahon (mid-$560s on May 21, 2026) suggests a lack of conviction or profit-taking from key executives.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (July 29, 2026): Failure to meet revised analyst estimates ($6.07-$6.94 EPS) could trigger further price declines and negative sentiment.
- 📅
Increased competitive pressure in PAH market (Ongoing): New entrants or stronger performance from rivals (e.g., Johnson & Johnson/Actelion, Bayer) eroding Tyvaso or Remodulin market share by 5-10% annually.
When to Reconsider
- 🚪
Exit if quarterly revenue falls below $750 million for two consecutive quarters, signaling a significant deceleration or reversal in growth.
- 🚪
Sell if operating margins decline by more than 300 basis points year-over-year for two consecutive quarters, indicating sustained commercial or cost control issues.
- 🚪
Exit if xenotransplantation program faces significant clinical setbacks or regulatory delays beyond 2028, removing the primary long-term upside catalyst.
Unlock UTHR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does United Therapeutics Corp (UTHR) Do?
Market Cap
$23.64B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Visit United Therapeutics Corp WebsiteInvestment Thesis
If United Therapeutics successfully executes the commercial launch and market penetration of Ralinepag and continues to expand the Tyvaso franchise through new formulations and indications, then the company could achieve a sustainable mid-to-high single-digit revenue growth rate annually, leading to EPS growth that justifies a premium valuation multiple. This is bullish because the market may be underestimating the cumulative impact of these pipeline assets beyond the current xenotransplantation moonshot.
Is UTHR Stock Undervalued?
Unlock the full AI analysis for UTHR
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
UTHR Price Targets & Strategy
12-Month Target
$619.42
Bull Case
$660.00
Bear Case
$480.00
Valuation Basis
24.4x forward P/E applied to estimated FY2026 EPS of $25.32, aligning with analyst consensus.
Entry Strategy
Consider dollar-cost averaging between $500-$520, near potential support levels, given the current price volatility post-earnings miss.
Exit Strategy
Take profit at target levels of $619-$660. Implement a stop-loss order below $480 to mitigate downside risk if Q2 earnings underperform significantly or key pipeline milestones are missed.
Portfolio Allocation
3-5% for moderate risk tolerance, reflecting long-term potential balanced against near-term execution risks and the unlikely 10x growth within the specified timeframe.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is UTHR Financially Healthy?
Valuation
P/E Ratio
18.36
Forward P/E
17.19
Profitability
Gross Margin
86.58%
Operating Margin
45.29%
Net Margin
40.61%
Return on Equity
19.24%
Revenue Growth
5.87%
EPS
$27.09
Balance Sheet
Current Ratio
6.60
Quick Ratio
6.28
Other
Beta (Volatility)
0.58
Does UTHR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is durable due to strong patent protection for its specialized therapies, the high cost and complexity of developing new treatments for rare diseases, and established physician relationships. The ongoing innovation in its pipeline, particularly xenotransplantation, further strengthens its long-term competitive position.
Moat Erosion Risks
- •Patent expirations on key revenue-generating drugs could expose them to generic competition, eroding market share and profitability.
- •Emergence of superior or more cost-effective therapies from competitors could disrupt its market dominance in PAH.
- •Regulatory challenges or delays in pipeline development could prevent new products from reaching the market, impacting future growth and moat expansion.
UTHR Competitive Moat Analysis
Sign up to see competitive advantages
UTHR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, mixed views due to strong long-term vision but recent financial underperformance.
Institutional Sentiment
Positive, with a 'Moderate Buy' consensus from analysts (11 Buy, 2 Hold), though tempered by recent estimate cuts (e.g., HC Wainwright on Q2 EPS).
Insider Activity (Form 4)
CFO James Edgemond sold 10,000 shares ($5.73 million) on May 26, 2026, and General Counsel Paul A. Mahon sold 8,300 shares (mid-$560s) on May 21, 2026, both preplanned 10b5-1 arrangements. Both were net sellers in the last 90 days.
Options Flow
Normal options activity, with no specific indications of significant institutional bearish or bullish positioning noted in the provided research.
Earnings Intelligence
Next Earnings
2026-07-29
Surprise Probability
Medium, given the Q1 miss and recent analyst estimate cuts, expectations may be reset, but performance pressure remains high.
Historical Earnings Pattern
Historically, UTHR has seen varied stock reactions to earnings, often influenced by pipeline updates and guidance alongside financial performance. The Q1 2026 miss led to negative sentiment.
Key Metrics to Watch
Competitive Position
Top Competitor
Johnson & Johnson (via Actelion acquisition)
Market Share Trend
Stable for established products like Remodulin and Orenitram, with potential for gaining share in PH with Tyvaso DPI and Ralinepag, but no specific market share data provided.
Valuation vs Peers
UTHR trades at a P/E of 20.99, which is generally in line with or slightly below the average for profitable, large-cap specialized biotechs with strong pipelines, especially given its growth potential. PEG ratio of 1.84 suggests it's reasonably valued for its anticipated growth.
Competitive Advantages
- •Established leadership and strong market presence in rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH).
- •Robust pipeline of innovative therapies with significant clinical validation (e.g., Ralinepag, advanced Tyvaso formulations).
- •Proprietary drug delivery systems and strong intellectual property protecting key products.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive UTHR Stock Higher?
Near-Term (0-6 months)
- •Jefferies Global Healthcare Conference (June 3, 2026): CFO participation could provide clarity on Q1 performance and Q2 outlook.
- •Q2 2026 Earnings Report (July 29, 2026): Strong Tyvaso and Ralinepag sales growth exceeding consensus ($805M revenue, $6.07-$6.94 EPS) could re-rate the stock positively.
Medium-Term (6-18 months)
- •Ralinepag (oral selective prostacyclin receptor agonist) commercialization ramp-up (H2 2026 - 2027): Successful market penetration in PAH could add $500M-$1B+ in annual peak sales.
- •Tyvaso DPI (dry powder inhaler) expansion into new geographies/indications (2027-2028): Further uptake beyond initial launch markets or approval for new patient populations, driving $300M-$500M incremental revenue.
Long-Term (18+ months)
- •Xenotransplantation clinical progress (2028+): First successful human trials demonstrating long-term organ viability could unlock a multi-billion dollar market opportunity, potentially justifying a significant valuation re-rating beyond 5 years.
- •Development of next-generation PH therapies or combination regimens (2028+): Introduction of novel treatment modalities that offer superior efficacy or convenience, leading to market share expansion and sustained revenue growth.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for UTHR?
- ✓
Watch quarterly revenue growth rates for Tyvaso and Ralinepag – a consistent year-over-year growth exceeding 15% would validate commercial execution.
- ✓
Monitor gross and operating margin trends – a reversal of Q1's margin compression and consistent improvement would signal operational efficiency.
- ✓
Track updates on xenotransplantation clinical milestones and regulatory interactions – any significant acceleration or positive data could be a major re-rating event.
Bull Case Analysis
Sign up free to see the bull case
Competing with UTHR
See how United Therapeutics Corp compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
United Therapeutics Corp UTHR | $23.6B | 5.0 | 18.4 | $3.1B | 40.6% | 5.9% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How United Therapeutics Corp Makes Money
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products for the treatment of rare, life-threatening diseases, predominantly affecting the cardiopulmonary system. The company primarily generates revenue by selling its approved pharmaceutical products, such as Remodulin, Tyvaso, and Orenitram, which are used to treat pulmonary arterial hypertension (PAH) and other rare diseases. Additionally, it invests heavily in research and development for future therapies, including groundbreaking xenotransplantation initiatives, aiming to provide an unlimited supply of transplantable organs.
Read Full Business Model BreakdownFAQ
What is the DVR Score for United Therapeutics Corp (UTHR)?
As of June 2, 2026, United Therapeutics Corp has a DVR Score of 5.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of United Therapeutics Corp?
United Therapeutics Corp's market capitalization is approximately $23.6B. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.
What ticker symbol does United Therapeutics Corp use?
UTHR is the ticker symbol for United Therapeutics Corp. The company trades on the NMS.
What is the risk level for UTHR stock?
Our analysis rates United Therapeutics Corp's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of UTHR?
United Therapeutics Corp currently has a price-to-earnings (P/E) ratio of 18.4. This is in line with broader market averages.
Is United Therapeutics Corp's revenue growing?
United Therapeutics Corp has reported revenue growth of 5.9%. The company is growing at a moderate pace.
Is UTHR stock profitable?
United Therapeutics Corp has a profit margin of 40.6%. This indicates strong profitability.
How often is the UTHR DVR analysis updated?
Our AI-powered analysis of United Therapeutics Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 2, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for UTHR (United Therapeutics Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.